A deliriant is a hallucinogenic substance that produces frank delirium — confusion, disorientation, and hallucinations perceived as completely real, with loss of insight into their drug-induced origin. The class is defined phenomenologically by that loss of insight, the criterion that separates deliriants from other hallucinogens. Most members reach this state through competitive antagonism of muscarinic acetylcholine receptors; a minority arrive at it through unrelated pathways.
The chemical core of the class is the tropane-alkaloid plants — Atropa belladonna, Datura, Hyoscyamus niger, and Mandragora — together with their alkaloids, principally scopolamine. Synthetic and over-the-counter anticholinergics including diphenhydramine and trihexyphenidyl reach the same endpoint by the same receptor mechanism.
Other members — Amanita muscaria, ibotenic acid, grayanotoxin, myristicin, and benzydamine — arrive at delirium by chemically unrelated routes but converge on the same loss of insight.
Deliriants are used recreationally far less commonly than psychedelics or dissociatives, and the experiences they produce are widely characterised in user reports as unpleasant and amnestic rather than insightful. Several tropane-alkaloid plants carry long ethnobotanical and folk-medicine histories; others enter the class through everyday clinical use of anticholinergic medications taken at supratherapeutic doses. Across the exposure range the picture moves from mild peripheral anticholinergic effects, through true hallucinations and severe disorientation, to a medical toxidrome at the high end.
Pharmacology
The majority of deliriants act through competitive, reversible antagonism of muscarinic acetylcholine receptors, with M1 blockade in the prefrontal cortex, hippocampus, and basal forebrain disrupting the cholinergic tone required for sustained attention, short-term memory, and reality-testing.[1] A minority of class members reach the same phenomenological endpoint through unrelated pathways.
| Mechanism | Representative members | How it reaches the shared endpoint |
|---|---|---|
| Muscarinic (M1/M2) receptor antagonism | scopolamine, Atropa belladonna, Datura, Hyoscyamus niger, Mandragora, diphenhydramine, trihexyphenidyl | Blocks central cholinergic signalling, disrupting attention, memory, and reality-testing[1] |
| NMDA / metabotropic glutamate agonism with GABAA agonism | Amanita muscaria, ibotenic acid | Ibotenic acid drives an excitatory delirium; in vivo decarboxylation to muscimol adds GABAergic sedation[2] |
| Persistent voltage-gated sodium-channel activation | grayanotoxin | Prevents channel inactivation, raising CNS release of acetylcholine, glutamate, and GABA; delirium appears secondary to systemic toxicity[3] |
| Mixed or incompletely characterised | myristicin, benzydamine | Proposed routes include weak MAO inhibition with amphetamine-like metabolites for myristicin and 5-HT2A agonism for benzydamine, with anticholinergic-type features at high exposures[4][5] |
The mechanistic detail matters less than the shared endpoint: reality-testing is disorganised to the point of frank delirium across the class, and the user cannot recognise the experience as drug-induced. Scopolamine's higher central penetrance produces deliriant effects at exposures with comparatively milder peripheral signs than atropine.[1]
Where the mechanism is anticholinergic, the peripheral toxidrome — inhibited sweating, dry mucous membranes, mydriasis, tachycardia, urinary retention, decreased bowel motility — follows directly from the same receptor blockade and gives clinicians a recognisable diagnostic picture.[6]
Substances
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| Scopolamine | Tropane alkaloid | Most centrally penetrant of the common tropane alkaloids; the pharmacological model for deliriant action[1] |
| Atropa belladonna | Tropane-alkaloid plant | Contains hyoscyamine, scopolamine, and atropine in highly variable ratios across plant parts[7] |
| Datura | Tropane-alkaloid plant | Alkaloid concentration varies enormously between plants and parts; no safe recreational dose window[7] |
| Hyoscyamus niger | Tropane-alkaloid plant | Historical European deliriant in folk-medicine and witchcraft traditions |
| Mandragora | Tropane-alkaloid plant | Long ethnobotanical history; produces the same anticholinergic toxidrome as its relatives |
| Diphenhydramine | Synthetic anticholinergic (H1 antihistamine) | Most common antihistamine source of anticholinergic toxicity in US Poison Control surveillance[6] |
| Trihexyphenidyl | Synthetic antiparkinsonian anticholinergic | Largest body of anticholinergic-abuse literature; documented tolerance and dependence[8][9] |
| Amanita muscaria | Mushroom (non-anticholinergic) | Reaches delirium via ibotenic-acid / muscimol GABAergic and glutamatergic action rather than muscarinic blockade[2] |
| Ibotenic acid | Mushroom alkaloid | NMDA and metabotropic glutamate agonist; decarboxylates to muscimol in vivo[2] |
| Grayanotoxin | Plant toxin (Ericaceae, "mad honey") | Sodium-channel toxin whose deliriant effects appear secondary to systemic and cardiovascular toxicity[3] |
| Myristicin | Nutmeg constituent | Disorganised mixed-mechanism intoxication with anticholinergic-type features at high exposures[4] |
| Benzydamine | OTC anti-inflammatory | Produces visual hallucinations perceived as fully real at very high oral doses; mechanism unsettled[10] |
These members differ markedly in chemistry and clinical profile, but each can produce a state in which the user cannot recognise their perceptions as drug-induced — the defining feature that holds the class together.
Subjective Effects
The shape of deliriant intoxication tracks rising exposure along a single phenomenological axis: deepening disorganisation of perception and judgement, with insight progressively lost.[1] The trajectory below applies most directly to the anticholinergic majority; Amanita, grayanotoxin, and benzydamine vary in timecourse and peripheral signs.
| Exposure | Characteristic effects |
|---|---|
| Low | Dry mouth, mild tachycardia, blurred near-vision, warm or flushed skin, mild sedation, and difficulty concentrating; cognition already impaired enough to preclude driving or operating machinery |
| Moderate–high | True visual hallucinations of people, animals, insects, or mundane objects perceived as completely real; fragmented or mumbling speech; conversations held with people who are not present; "carphologia" — repetitive picking at invisible objects or at clothing — as a classic sign; severe disorientation to time and place; reality-based reassurance no longer effective[6] |
| High | Profound delirium with incoherent behaviour, hyperthermia from inhibited sweating, severe tachycardia, urinary retention, decreased bowel motility, and risk of seizures and cardiovascular compromise[6] |
Anterograde and retrograde amnesia for the episode is the rule rather than the exception with anticholinergic deliriants, distinguishing the class from psychedelics, where memory of the session is typically preserved. The same axis that produces the sought-after hallucinations also drives the medical toxidrome — there is no part of the exposure range at which only the "interesting" effects appear without the dangerous ones, and the margin narrows further as exposure rises.
Safety
Risk profile
The class-defining acute danger of deliriants is behavioural: because hallucinations are perceived as completely real and insight is absent, individuals in a deliriant state may act on what they perceive — fleeing nonexistent threats, wandering into traffic, climbing structures, jumping from heights, or becoming agitated and physically dangerous to themselves or to bystanders.Anyone caring for someone in a deliriant state should assume they cannot be reasoned with, prioritise physical safety, and keep them in a quiet, low-stimulus environment with a sober companion present until the episode passes.
Beyond behavioural harm the anticholinergic toxidrome carries its own medical risks. Inhibition of sweating combined with agitation creates serious heat-stroke risk; hyperthermia is one of the principal causes of severe morbidity in anticholinergic poisoning.[6] Tachycardia is near-universal, and at toxic exposures QRS widening and ventricular arrhythmias are possible.[6]
Seizures occur at high exposures, particularly with tropane-alkaloid plants and with diphenhydramine, and add the further risk of rhabdomyolysis.[6] Grayanotoxin reverses the cardiovascular picture, producing bradycardia and atrioventricular block rather than tachycardia.[3]
For the tropane-alkaloid plants there is effectively no safe recreational dose window. Alkaloid content varies enormously between individual plants, plant parts, and growing conditions, and a preparation from one plant may be subtoxic while the same apparent quantity from another causes life-threatening toxicity.[7] Neither drying nor boiling reliably destroys the alkaloids.[7]
Accidental ingestion and drastic underestimation of potency are recurring patterns in Datura and Atropa belladonna poisonings. Combining two deliriants produces additive receptor blockade and sharply escalates toxidrome severity, and adding alcohol or other depressants can deepen central disorganisation while masking peripheral warning signs.
Anticholinergic exposures account for thousands of reports to US Poison Control Centers each year, with diphenhydramine the most common antihistamine source in that surveillance.[6] For confirmed anticholinergic delirium, physostigmine — a reversible acetylcholinesterase inhibitor that crosses the blood–brain barrier — is the specific antidote, and in the published case-series literature it controlled agitation and reversed delirium more reliably than benzodiazepines.[1] Physostigmine is not appropriate for the non-anticholinergic members of the class, where supportive care is the primary approach.
Tolerance & dependence
Tolerance to anticholinergic effects develops with regular use and has been documented for both trihexyphenidyl and biperiden.[8][11] A systematic review of 48 articles found the pattern consistent across centrally-acting anticholinergics, with the largest abuse literatures centred on trihexyphenidyl and benztropine.[9] Escalation as effects diminish progressively narrows the gap between the psychoactive exposure and a medically dangerous one.
Physical dependence is documented in the case literature, most often in patients prescribed anticholinergics for the extrapyramidal effects of antipsychotics, but also in recreational contexts and in over-the-counter diphenhydramine misuse.[9] The typical trajectory is dose escalation, a subjective need for the drug to feel normal, and a recognisable withdrawal syndrome on cessation.[8][11]
Abrupt discontinuation after sustained high-dose use produces a cholinergic-rebound syndrome — excessive salivation and sweating, nausea, vomiting, diarrhoea, anxiety, and insomnia — the predictable inverse of the anticholinergic state. Unlike alcohol or benzodiazepine withdrawal, anticholinergic withdrawal does not carry a well-established risk of life-threatening seizures, though the discomfort can be severe and a gradual reduction is the appropriate approach.
Recovery
Acute deliriant toxicity, when managed with supportive care or with physostigmine where indicated, typically resolves within hours to a day or two.[1] Recovery from established dependence on prescription anticholinergics is best handled with medical supervision: a clinician can structure a gradual reduction that minimises withdrawal discomfort and the risk of re-escalation.Cognitive effects, particularly memory disruption, may take longer to settle after severe or prolonged exposures. If you or someone you know has had a deliriant medical emergency or is misusing an anticholinergic medication, a clinician or a poison-control service is the right starting point.
Recovery resources, crisis lines, and support pathways → View all
Members
references
- [1]
- [2] ^abcStoeva-Grigorova S, Yarabanova I, Radeva-Ilieva M, Ivanova D, Zlateva S, Marinov P (2025) Acute Amanita muscaria Toxicity: A Literature Review and Two Case Reports in Elderly Spouses Following Home Preparation — Toxins doi:10.3390/toxins17120570
- [3] ^abcdJansen, S.A. and Kleerekooper, I. and Hofman, Z.L.M. and Kappen, I.F.P.M. and Stary-Weinzinger, A. and van der Heyden, M.A.G. (2012) Grayanotoxin Poisoning: 'Mad Honey Disease' and Beyond — Cardiovascular Toxicology doi:10.1007/s12012-012-9162-2
- [4] ^abSeneme, E.F. and dos Santos, D.C. and Rodrigues Silva, E.M. and Moreira Franco, Y.E. and Longato, G.B. (2021) Pharmacological and Therapeutic Potential of Myristicin: A Literature Review — Molecules doi:10.3390/molecules26195914
- [5] ^Chiappini, S. and Miuli, A. and Mosca, A. and Pettorruso, M. and Guirguis, A. and Corkery, J.M. and Martinotti, G. and Di Giannantonio, M. and Schifano, F. (2021) The Benzydamine Experience: A Systematic Review of Benzydamine Abuse — Current Neuropharmacology doi:10.2174/1570159x19666210113151136
- [6]